Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000606113 | SCV000718402 | likely benign | not specified | 2017-04-12 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Color Diagnostics, |
RCV001190492 | SCV001357993 | likely benign | Hereditary cancer-predisposing syndrome | 2019-06-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002063145 | SCV002439928 | likely benign | Fanconi anemia complementation group O | 2025-01-16 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002498917 | SCV002804887 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 3; Fanconi anemia complementation group O | 2022-04-13 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001190492 | SCV004849258 | uncertain significance | Hereditary cancer-predisposing syndrome | 2015-12-06 | criteria provided, single submitter | clinical testing | The c.905-20A>G intronic alteration consists of a A to G substitution 20 nucleotides before coding exon 7 in the RAD51C gene. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |